32 active shortage notices across 6 countries · 3 anticipated.
Last updated 24 Sept 2026 · sourced from official medicines regulators
| Country | Severity | Notices | Since | Est. resolution | Source |
|---|---|---|---|---|---|
| Netherlands | high | 24 | 11 Dec 2025 | — | CBG-MEB |
| Canada | medium | 3 | 29 Jul 2025 | 14 Apr 2026 | HC |
| Belgium |
| medium |
| 2 |
| 17 Jun 2026 |
| 22 Sept 2026 |
| FAMHP |
| United States | medium | 1 | 18 Sept 2026 | — | FDA |
| Bosnia and Herzegovina | medium | 1 | 11 Dec 2025 | 31 Dec 2026 | ALMBIH |
| Malaysia | medium | 1 | 1 Jan 2024 | — | NPRA |
Yes. As of the latest regulator updates, Rivastigmine has 32 active shortage notices across 6 countries (Netherlands, Canada, Belgium, United States, Bosnia and Herzegovina, Malaysia). Status is refreshed daily from official regulatory sources.
Regulators attribute the current Rivastigmine shortages to product discontinuation, manufacturing problems, unexpected increases in demand. The exact cause varies by country and product — each notice on this page links to the official source.
Regulator-estimated resolution dates currently range from 15 Sept 2025 to 31 Dec 2026, depending on country and product. These estimates come from the manufacturers via regulators and often change — check the per-country table above for the latest.
Every shortage notice on this page is scraped daily from an official national medicines regulator (such as the FDA, TGA, MHRA or EMA) and linked back to its source. Mederti aggregates 40+ regulators across 50+ countries and never publishes unsourced shortage claims.
Free for individual pharmacists and clinicians — watchlists, email alerts, alternatives and country-by-country product detail.
Create a free accountData on this page is aggregated from official national medicines regulators and updated daily. It is provided for information only and requires verification before clinical use. Mederti is not affiliated with or endorsed by any regulator.